Diagnostic role of complete blood count in pleural effusions
Citation
Balci, A., & Aydin, S. (2021). Diagnostic role of complete blood count in pleural effusions. Medicine, 10(2), 539-44.Abstract
Pleural effusion (PE) can be seen during the course and treatment of many malignant or benign diseases. Congestive heart failure and pneumonia are the most common
causes of benign pleural effusion (BPE), while lung and breast cancer are the most common causes of malignant pleural effusion (MPE). MPE indicates that the disease
is extensive or advanced and the average survival is 4-12 months. In this study, we aimed to investigate the changes in complete blood count parameters in patients with
benign and malignant PE. Patients who underwent thoracentesis and pleural fluid analysis between January 1, 2015 and December 1, 2020 were included in the study.
Demographic characteristics, pathological diagnoses, pleural fluid cell analysis, blood parameters of the patients were recorded. The patients were divided into two groups
according to their MPE and BPE detection status. Complete blood count parameters, Systemic Inflammatory Index (SII), Platelet / Lymphocyte Ratio (PLR), Monosin /
Lymphocyte Ratio (MLR), Eosinophil / Lymphocyte Ratio (ELR) and Neutrophil / Lymphocyte Ratio (NLR) values were found in both groups and were recorded and
compared. 240 patients with PE and meeting the study criteria were included in the study. There were 154 (64.17%) patients with BPE and 86 (35.83%) patients with MPE.
In patients with MPE, WBC (103 / mL) 10.22 (2.32-27.50) (p = 0.001), Neutrophil (103 / UL) 8 (0.48-24.25) (p <0.001), Monocyte (103 / UL) 0.7 (0-1.9) (p = 0.002)
were detected. In addition, SII 1868.54 (139.88-16862.63) (p = 0.001), NLR 6.68 (0.38-92.91) (p = 0.001), MLR 0.58 (0-4.46) (p = 0.038) were detected. All these values
were statistically higher than the patients with BPE. SII, MLR and NLR values are cheap and easily applicable parameters that can help in the differentiation of malignant
and benign pleural effusion, in predicting the prognosis of patients with MPE and in treatment planning.